[Clinical significance of and treatment options for increased lipoprotein(a)]
- PMID: 24733102
- DOI: 10.1556/OH.2014.29877
[Clinical significance of and treatment options for increased lipoprotein(a)]
Abstract
Lipoprotein(a) has been shown to be associated with an increased incidence of cardiovascular diseases for decades. However, only recent research revealed more about its physiological function and its role in the development of cardiovascular diseases. The authors summarize the physiological role of lipoprotein(a), causes and treatment of elevated lipoprotein(a) level, and the association between lipoprotein(a) and cardiovascular diseases.
Évtizedek óta ismert, hogy a lipoprotein(a) összefüggésbe hozható a cardiovascularis betegségek fokozott előfordulásával, azonban csak az utóbbi évek kutatásai alapján kezdjük megismerni a fiziológiás és az érrendszeri betegségek kialakulásában játszott szerepét. A szerzők részletesen foglalkoznak a lipoprotein(a) fiziológiás szerepével, a magas lipoprotein(a)-szint okaival, annak csökkentési lehetőségeivel, illetve a lipoprotein(a) és a cardiovascularis betegségek közötti kapcsolattal. Orv. Hetil., 2014, 155(16), 607–614.
Keywords: LPA gene; LPA gén; Lp(a); aferézis; apheresis; cardiovascular diseases; cardiovascularis betegségek.
Similar articles
-
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):22-26. doi: 10.1007/s11789-017-0090-3. Clin Res Cardiol Suppl. 2017. PMID: 28233269 Free PMC article. Review.
-
Latest developments in the treatment of lipoprotein (a).Curr Opin Lipidol. 2014 Dec;25(6):452-60. doi: 10.1097/MOL.0000000000000126. Curr Opin Lipidol. 2014. PMID: 25318824 Review.
-
Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):12-17. doi: 10.1007/s11789-017-0083-2. Clin Res Cardiol Suppl. 2017. PMID: 28185213 Free PMC article. Review.
-
Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.Atheroscler Suppl. 2015 May;18:263-7. doi: 10.1016/j.atherosclerosissup.2015.02.039. Atheroscler Suppl. 2015. PMID: 25936335 Review.
-
Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy.Eur J Prev Cardiol. 2024 Jun 3;31(8):e62-e64. doi: 10.1093/eurjpc/zwae054. Eur J Prev Cardiol. 2024. PMID: 38470832 No abstract available.
Cited by
-
Emerging risk biomarkers in cardiovascular diseases and disorders.J Lipids. 2015;2015:971453. doi: 10.1155/2015/971453. Epub 2015 Apr 8. J Lipids. 2015. PMID: 25949827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
